Flávia Vieira

Flávia Vieira

Auto-generated profile, based on publicly available information

Flávia Vieira

Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria do Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil. Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
GLGustavo C. Leal
Gustavo C. Leal
IBIgor D. Bandeira
Igor D. Bandeira
FCFernanda S. Correia-Melo
Fernanda S. Correia-Melo
MTManuela Telles
Manuela Telles
RMRodrigo P. Mello
Rodrigo P. Mello
LQLucas C. Quarantini
Lucas C. Quarantini

1 March 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
FCFernanda S. Correia-Melo
Fernanda S. Correia-Melo
GLGustavo C. Leal
Gustavo C. Leal
FVFlávia Vieira
Flávia Vieira
AJAna Paula Jesus-Nunes
Ana Paula Jesus-Nunes
RMRodrigo P. Mello
Rodrigo P. Mello
LQLucas C. Quarantini
Lucas C. Quarantini

1 September 2018 in Medicine
Verified
Journal Article
Open access
FCFernanda S. Correia-Melo
Fernanda S. Correia-Melo
GLGustavo C. Leal
Gustavo C. Leal
MCMichelle S. Carvalho
Michelle S. Carvalho
AJAna Paula Jesus-Nunes
Ana Paula Jesus-Nunes
CFCarolina B.N. Ferreira
Carolina B.N. Ferreira
LQLucas C. Quarantini
Lucas C. Quarantini
The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medication when compared to ketamine in the treatment of patients with treatment-resistant depression. This study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants will receive a single infusion of either esketamine (0.25 mg/kg) or ketamine (0.5 mg/kg) over 40 minutes. The primary outcome will be the difference in remission rates between the 2 treatment arms at 24 and 72 hours after drug infusion. Secondary outcomes will include other timepoints, measurements of cognition, dissociation, and blood biomarkers. A head-to-head study is the best way to evaluate whether the esketamine is in fact comparable to the racemic ketamine in terms of both efficacy and safety, and, if positive, it would be an initial step to increase the access to that type of treatment worldwide. The study was approved by the local Institutional Review Board (University Hospital Professor Edgard Santos—Federal University of Bahia—Number: 46657415.0.0000.0049). Subjects will only participate after voluntarily agreeing and signing the Informed Consent Form. The study findings will be published in peer-reviewed journals and presented at national and international conferences. This trial has been registered in the Japan Primary Registries Network (JPRN): UMIN000032355, which is affiliated with the World Health Organization.

5 August 2021 in Harvard Review of Psychiatry
Verified
Journal Article
Closed access
BSBreno Ba Souza-Marques
Breno Ba Souza-Marques
CSCassio Msc Santos-Lima
Cassio Msc Santos-Lima
LALucas Araújo-De-Freitas
Lucas Araújo-De-Freitas
FVFlávia Ba Vieira
Flávia Ba Vieira
AJAna Paula Jesus-Nunes
Ana Paula Jesus-Nunes
ASAline S. Sampaio
Aline S. Sampaio
Learning objective: After participating in this activity, learners should be better able to: • Analyze the effects of ketamine and esketamine on individuals with treatment-resistant depression Introduction: Cognitive impairment is commonly present in individuals with treatment-resistant depression, especially in attention, memory, and executive functions. These deficits are related to symptom severity, remission rates, and functional impairments during and after the acute phase of the disorder. Ketamine, an N-methyl-D-aspartate antagonist previously used as an anesthetic, brings promising antidepressant results. This study systematically reviews the neurocognitive effects of ketamine and esketamine in patients with treatment-resistant major depressive disorder. Methods: Systematic searches were conducted at Embase, PubMed, and PsycINFO using the terms depression, ketamine, and cognition. Title, abstract, and full-text reading were conducted independently by two of the authors (BSM and CSL). Risk of bias, study design, neuropsychological outcomes, and neuroimaging data were recorded. Results: From a total of 997 hits, 14 articles were included. One study reported cognitive impairment after ketamine treatment for processing speed and verbal memory. Five studies reported improvements in processing speed, verbal memory, visual memory, working memory, or cognitive flexibility. The esketamine study suggested no changes to performance. Lower attention, slower processing speed, and higher working memory are reported as predictors of antidepressant response. Brain areas for emotional and reward processing, including the amygdala, insula, and orbitofrontal cortex, show a normalizing tendency after ketamine. Conclusions: Ketamine and esketamine do not seem to exert significant deleterious neurocognitive effects in the short or long term in individuals with treatment-resistant depression. Results suggest neuropsychological functions and brain areas commonly impaired in treatment-resistant depression may especially benefit from subanesthetic ketamine infusions. Key questions that remain unanswered are discussed.

1 September 2021 in Psychiatry Research
Verified
Journal Article
Closed access
LALucas Araújo-De-Freitas
Lucas Araújo-De-Freitas
CSCassio Santos-Lima
Cassio Santos-Lima
EMEuclides Mendonça-Filho
Euclides Mendonça-Filho
FVFlávia Vieira
Flávia Vieira
RFRicardo J A F França
Ricardo J A F França
LQLucas C Quarantini
Lucas C Quarantini

1 December 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MSMarcel Henrique Silva-Moraes
Marcel Henrique Silva-Moraes
ABAna Cecília Bispo-Torres
Ana Cecília Bispo-Torres
JBJudah L Barouh
Judah L Barouh
PLPedro H Lucena
Pedro H Lucena
GAGiulia Armani-Franceschi
Giulia Armani-Franceschi
IBIgor D Bandeira
Igor D Bandeira